Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS SEC filings (Ticker: SHPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Shuttle Pharmaceuticals means wading through pages of radiation-sensitizer chemistry, trial protocols, and financing footnotes. If finding R&D burn rates or decoding licensing terms inside a 10-K feels overwhelming, you鈥檙e not alone.
Stock Titan solves that problem. Our AI surfaces the numbers and narrative that matter鈥攃ash runway, Phase 2 milestones, dilution risks鈥攄irectly from every filing type. Need the Shuttle Pharmaceuticals annual report 10-K simplified? We highlight how Ropidoxuridine鈥檚 glioblastoma study influences revenue projections. Curious about a fresh capital raise? The latest Shuttle Pharmaceuticals 8-K material events explained appear with plain-English context the moment EDGAR posts.
Here鈥檚 what you鈥檒l find on this page:
- AG真人官方-time alerts for Shuttle Pharmaceuticals Form 4 insider transactions real-time, so you can see when executives buy or sell shares.
- Concise AI notes inside every Shuttle Pharmaceuticals quarterly earnings report 10-Q filing, turning trial-cost tables into readable trends.
- Side-by-side comparisons of equity issuances, royalty obligations, and Shuttle Pharmaceuticals proxy statement executive compensation disclosures.
Whether you鈥檙e monitoring Shuttle Pharmaceuticals insider trading Form 4 transactions before a data read-out or seeking a quick Shuttle Pharmaceuticals earnings report filing analysis, our platform answers the exact questions professionals ask: 鈥渦nderstanding Shuttle Pharmaceuticals SEC documents with AI鈥�. All filings, all the time鈥攅xplained simply.
Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G reporting shared beneficial ownership of 56,237 shares of Shuttle Pharmaceuticals Holdings, Inc. common stock, representing 4.99% of the class. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and pursuant to an investment management agreement exercises voting and investment power over those securities. Mr. Boyd, as managing member of Armistice Capital, is reported with the same shared voting and dispositive power. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control.
Steven M. Richards, a director of Shuttle Pharmaceuticals Holdings (SHPH), was granted 29,240 Restricted Stock Units (RSUs) on 08/08/2025, as reported on a Form 4 signed 08/12/2025. The filing states each RSU represents the contingent right to receive one share of common stock at no cash price.
One-third of the RSUs will vest on each of 08/08/2026, 08/08/2027 and 08/08/2028, meaning the award converts into a total of 29,240 shares if all vest according to the stated schedule. The Form 4 lists the ownership form as direct and shows the grant was reported under a non-cash equity award.
Shuttle Pharmaceuticals director Oleh Nabyt was granted 29,240 restricted stock units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock and is reported with a $0 price. The RSUs vest in three equal installments: one-third on 08/08/2026, one-third on 08/08/2027 and one-third on 08/08/2028. The award is reported as a direct beneficial holding and, if fully vested and converted, would result in receipt of up to 29,240 shares of common stock.
George Scorsis, a director of Shuttle Pharmaceuticals Holdings (SHPH), was granted 29,240 Restricted Stock Units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock. The award is reported as direct beneficial ownership by the reporting person.
One-third of the RSUs vest on each of 08/08/2026, 08/08/2027 and 08/08/2028, meaning up to 29,240 common shares may be issued to satisfy the award over three years if vesting conditions are met. The grant is a standard equity compensation award for a board member with a multi-year retention schedule.
Joseph Tung, a director of Shuttle Pharmaceuticals Holdings (SHPH), was granted 29,240 restricted stock units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock and the award was recorded at $0. The RSUs vest in three equal installments, with one-third vesting on each of 08/08/2026, 08/08/2027 and 08/08/2028, and the reported ownership form is direct. Following this reported transaction, the RSUs correspond to 29,240 underlying shares.
The filing discloses an equity award that aligns a director with shareholder interests via long-term vesting, but it does not provide the company鈥檚 total outstanding share count or other compensation terms needed to assess dilution or material financial impact.
Timothy J. Lorber, Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc. (SHPH), was granted a total of 54,094 restricted stock units (RSUs) in transactions dated 08/08/2025. Each RSU represents a contingent right to receive one share of common stock and the grants were reported on a Section 16 Form 4.
The awards are split into two grants: 29,240 RSUs that vest one-third on each of 08/08/2026, 08/08/2027 and 08/08/2028, and 24,854 RSUs that vest on 02/08/2026. Both grants show an acquisition price of $0 and are held in a direct ownership form.
Shuttle Pharmaceuticals (SHPH) reported continued development-stage operations with no revenue and a six-month net loss of $6,759,472. Cash and cash equivalents rose to $4,817,672 at June 30, 2025 from $1,920,144 at year-end 2024, driven by net financing proceeds of approximately $8.78 million. Total assets were $5.50 million and stockholders' equity increased to $3.61 million as shares outstanding expanded to 1,070,773.
The company disclosed a substantial doubt about its ability to continue as a going concern: management states existing cash, equity proceeds and an undrawn $2.0 million revolving note are not expected to fund operations and clinical trials through the next 12 months. Material items include reverse stock splits to meet Nasdaq requirements, equity financings in March and June 2025, accelerated stock-based compensation of about $0.5 million from RSU modifications, and a $2.0 million payment to an IR agency recorded as expense.
Shuttle Pharmaceuticals Holdings has filed a Form D notice for an exempt securities offering under Rule 506(b). The company has successfully raised $4,250,000 through the offering, which was completed on June 20, 2025, with no remaining amount to be sold.
Key details of the offering:
- Securities offered include equity, options/warrants, and securities to be acquired upon exercise
- WestPark Capital served as broker-dealer with sales commissions of $170,000
- Total of 1 investor participated in the offering
- Offering not intended to last more than one year
The company's leadership includes Christopher Cooper (CEO), Peter Dritschilo (President/COO), Mira Jung (Chief Scientific Officer), Tyvin Rich (Chief Medical Officer), and Timothy Lorber (CFO). The pharmaceutical company is headquartered in Gaithersburg, Maryland, and was incorporated in Delaware over five years ago.
Shuttle Pharmaceuticals Holdings (NASDAQ:SHPH) has entered into a private placement agreement with an accredited investor on June 20, 2025. The company will sell 21,924 shares of common stock at $3.60 per share and 1,158,953 pre-funded warrants at $3.599 per warrant with a $0.001 exercise price.
The agreement includes a registration rights requirement to file within 10 days and achieve effectiveness within 90-120 days. The company and insiders agreed to a 60-day lock-up period. WestPark Capital served as placement agent, receiving a 4% fee of gross proceeds plus expense reimbursement.
FAQ
What is the current stock price of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
What is the market cap of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
